INFYNITY BIOMARKERS was co-founded by Dr. Maan Zrein and Dr. Samih Darwazah.

Dr Maan Zrein directed for over 18 years various R & D programs applied to the IVD industry. His work within Adaltis (previously known as BioChem Immunosystems and IAF BioChem in Canada), Diagast Laboratories (France) and Innogenetics (Belgium) led to the marketing of innovative products in the fields of infectious diseases and immune disorders, of which some are recommended by the World Health Organization.

As Chief Scientific Officer, Dr. Zrein is managing InfYnity Biomarker R&D department.

Dr. Samih Darwazah graduated from St. Louis College of Pharmacy, Missouri. After 12 years with Eli Lilly, he founded the company Hikma Pharmaceuticals Ltd. in 1978 and grew it into a profitable big pharma company before its introduction to the London Stock Exchange (LSE: HIK) in 2005. Dr. Samih Darwazah held positions as Senator, non-executive Chairman of Hikma Pharmaceuticals, Chairman of the Capital Bank, and Chairman of Labatec Pharma AG.

Both partners have been pursuing collaborations for over ten years. Their common goal is to conduct the starting company to a leading position in the field of biomarkers of clinical interest.


PULSALYS supported INFYNITY BIOMARKERS during its inception phase when a collaborative project with CNRS and HCL was implemented